does glp 1 work for perimenopause Why I'm Microdosing a GLP-1 in – Nicole Jardim GLP-1 Weight Loss in Menopause:

Pulsatile versus tonic GH release biology: Studies comparing the downstream biological consequences of pulsatile GH release (produced by short-acting GHRH analogues and GHRPs) versus tonic GH elevation (produced by long-acting GHRH-DAC variants or continuous GH infusion) established that pulsatile GH patterns are more potent drivers of hepatic IGF-1 production and anabolic GH signalling than equivalent total GH doses delivered continuously providing the physiological rationale for preserving pulsatile GH release characteristics in GH secretagogue research designs

Is the method compatible with religious beliefs and/or cultural practices

Clinical Benefits of Microdosing: Reduced Side Effects: Lower starting doses minimize nausea, vomiting, and other gastrointestinal symptoms that can lead to treatment discontinuation Individualized Titration: Ability to make small incremental adjustments based on patient response and tolerance Cost Effectiveness: Extended use of each medication vial, making treatment more accessible Improved Adherence: Better tolerability leads to sustained treatment compliance Dosing Protocols for Microdosing: Research supports starting with doses as low as 0.15 mg per week for compounded semaglutide, with gradual titration based on individual response.[5] The flexible dosing allows providers to find the optimal therapeutic dose for each patient while maintaining safety and efficacy

Possible Side Effects : Bloating, gas, and mild digestive discomfort, usually temporary